首页|期刊导航|中国输血杂志|异基因造血干细胞移植患者行治疗性血浆置换不良反应的影响因素分析

异基因造血干细胞移植患者行治疗性血浆置换不良反应的影响因素分析OA

Risk factors for therapeutic plasma exchange-related adverse events in patients undergoing allogeneic hematopoietic stem cell transplantation

中文摘要英文摘要

目的 探讨异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)患者行治疗性血浆置换(therapeutic plasma exchange,TPE)过程中不良反应的发生情况及其独立危险因素,为临床安全实施TPE 提供参考依据.方法 回顾性分析 2022 年 3 月至 2023 年 12 月于本科接受 TPE 治疗的 167 例 allo-HSCT 患者的临床资料,共计 385 次 TPE 治疗.根据是否发生不良反应将患者分为两组,收集其基线资料、置换参数及临床特征,采用单因素及多因素 Firth Logistic 回归分析筛选不良反应的独立危险因素.结果 167 例 allo-HSCT 患者共接受 385 次 TPE 治疗,33 例(19.8%)发生 TPE 相关不良反应.其中过敏反应最常见(18 例,占 54.5%),其次为血压波动(11 例,33.3%)和低钙血症(4 例,12.1%).不良反应严重程度以Ⅱ级为主(23 例,69.7%),无Ⅳ级(死亡)病例.单因素分析显示,不同红细胞比容(hematocrit,HCT)分级(<20%、20%~30%、>30%)组间不良反应发生率差异有统计学意义(Fisher 精确检验 P=0.022),经 Bonferroni 校正后,两两比较的显著性水平设为 0.016 7,任一配对比较结果均未达显著水平(校正后 P>0.016 7).多因素 Firth Logistic 回归分析显示,HCT 连续变量升高(OR=1.07,95%CI:1.01~1.13,P=0.020)及因细胞因子释放综合征(cytokine release syndrome,CRS)行 TPE 治疗(OR=9.21,95%CI:1.25~78.00,P=0.030)可能是 TPE 相关不良反应的独立危险因素.ROC 曲线分析显示,HCT 预测不良反应的 AUC 为 0.67(95%CI:0.57~0.77),最佳临界值为 24.5%,敏感性 60.6%,特异性 75.4%.按该临界值进行分组,HCT≥24.5%组患者的不良反应发生率显著高于HCT<24.5%组(37.7%vs 11.4%,P<0.001).结论 allo-HSCT患者 TPE 不良反应以过敏反应为主,其风险与 HCT 升高及 CRS 行 TPE 治疗相关.HCT≥24.5%(AUC=0.67)具中等预警价值,但不宜作为独立决策依据,需联合其他指标综合评估,CRS 相关结论待扩大样本验证.优化预充方案并加强围置换期监测,是提升安全性的关键.

Objective To investigate the incidence and independent risk factors of adverse events(AEs)associated with therapeutic plasma exchange(TPE)in patients undergoing allogeneic hematopoietic stem cell transplantation(allo-HSCT),and to provide evidence to support the safe use of TPE in clinical practice.Methods This retrospective study in-cluded 167 allo-HSCT recipients who underwent a total of 385 TPE procedures between March 2022 and December 2023.Patients were divided into two groups according to the occurrence of TPE-related AEs.Baseline characteristics,plasma ex-change parameters,and clinical features were collected.Univariate analysis and multivariable Firth logistic regression were performed to identify independent risk factors for AEs.Results A total of 385 TPE procedures were performed in 167 allo-HSCT patients,and 33 patients(19.8%)experienced TPE-related AEs.Among the 33 patients who experienced AEs,al-lergic reactions were the most common(n=18,54.5%),followed by blood pressure fluctuations(n=11,33.3%)and hy-pocalcemia(n=4,12.1%).Most AEs were classified as grade II(n=23,69.7%),and no grade IV(fatal)events were observed.Univariate analysis demonstrated a significant difference in the incidence of AEs among different hematocrit(HCT)categories(<20%,20%-30%,and>30%)(Fisher's exact test,P=0.022).Although the overall difference was statistically significant,none of the pairwise comparisons remained significant after Bonferroni correction(adjusted P>0.0167).Multivariable Firth logistic regression identified higher HCT levels,analyzed as a continuous variable(OR=1.07,95%CI:1.01-1.13,P=0.020),and TPE performed for cytokine release syndrome(CRS)(OR=9.21,95%CI:1.25-78.00,P=0.030)as potential independent risk factors for TPE-related AEs.Receiver operating characteristic(ROC)curve analysis showed that HCT had an AUC of 0.67(95%CI:0.57-0.77)for predicting AEs,with an optimal cutoff value of 24.5%,a sensitivity of 60.6%,and a specificity of 75.4%.Using this cutoff,the AEs rate was significantly higher in patients with HCT≥24.5%than in those with HCT<24.5%(37.7%vs 11.4%,P<0.001).Conclusion A-mong allo-HSCT patients receiving TPE,allergic reactions were the predominant AEs.Higher HCT levels and TPE per-formed for CRS may be associated with an increased risk of AEs.HCT≥24.5%may help identify patients requiring inten-sified monitoring,although its discriminatory ability is moderate(AUC=0.67)and it should not be used as a standalone criterion for clinical decision-making.Findings regarding the CRS subgroup require validation in larger cohorts.Optimizing extracorporeal circuit priming and strengthening peri-procedural monitoring may help improve the safety of TPE.

秦敬媛;隆靖;袁丽莉;张月梅;乔佳丽;杨雪莲;尹晴雪;陈娟

河北燕达陆道培医院 血细胞单采室,河北 廊坊 065000北京陆道培医院 数据中心,北京 100176河北燕达陆道培医院 医学检验科,河北 廊坊 065000河北燕达陆道培医院 血细胞单采室,河北 廊坊 065000河北燕达陆道培医院 血细胞单采室,河北 廊坊 065000河北燕达陆道培医院 血细胞单采室,河北 廊坊 065000河北燕达陆道培医院 血细胞单采室,河北 廊坊 065000河北燕达陆道培医院 血细胞单采室,河北 廊坊 065000

医药卫生

血浆置换异基因造血干细胞移植不良反应供者特异性抗HLA抗体细胞因子释放综合征

plasmapheresisallogeneic hematopoietic stem cell transplantationadverse reactionsdonor-specific anti-HLA antibodiescytokine release syndrome

《中国输血杂志》 2026 (9)

1254-1261,8

10.13303/j.cjbt.issn.1004-549x.2026.09.013

评论